These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11175636)

  • 21. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
    Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
    Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A distinctive melanocytic lesion associated with melanoma-prone dysplastic naevus syndrome: the hybrid naevus.
    Schubert C; Parwaresch R; Rudolph P
    Virchows Arch; 2001 Feb; 438(2):166-72. PubMed ID: 11253119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclin D1 expression in melanocytic lesions of the skin.
    Ramirez JA; Guitart J; Rao MS; Diaz LK
    Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi.
    Touab M; Arumi-Uría M; Barranco C; Bassols A
    Am J Clin Pathol; 2003 Apr; 119(4):587-93. PubMed ID: 12710131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and distribution of transforming growth factor-alpha within melanocytic lesions.
    Nanney LB; Coffey RJ; Ellis DL
    J Invest Dermatol; 1994 Nov; 103(5):707-14. PubMed ID: 7963661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Focal melanocytic atypia in dysplastic nevus cell nevi. Results of a serial section study].
    Sigg C; Pelloni F; Schnyder UW
    Hautarzt; 1989 Nov; 40(11):701-7. PubMed ID: 2606669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The presence of dysplastic nevus remnants in malignant melanomas. A population-based study of 551 malignant melanomas.
    Hastrup N; Osterlind A; Drzewiecki KT; Hou-Jensen K
    Am J Dermatopathol; 1991 Aug; 13(4):378-85. PubMed ID: 1928622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histopathologic recognition and grading of dysplastic melanocytic nevi: an interobserver agreement study.
    Duncan LM; Berwick M; Bruijn JA; Byers HR; Mihm MC; Barnhill RL
    J Invest Dermatol; 1993 Mar; 100(3):318S-321S. PubMed ID: 8440913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin D1 and p16 Expression in Blue Nevi and Malignant Melanoma.
    Donigan JM; De Luca J; Lum C
    Appl Immunohistochem Mol Morphol; 2017 Feb; 25(2):91-94. PubMed ID: 26766120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell kinetics of melanocytes in common and dysplastic nevi and in primary and metastatic cutaneous melanoma.
    Urso C; Bondi R; Balzi M; Scubla E; Mauri P; Becciolini A; Tarocchi S; Vallecchi C
    Pathol Res Pract; 1992 Apr; 188(3):323-9. PubMed ID: 1625997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels.
    Specht K; Haralambieva E; Bink K; Kremer M; Mandl-Weber S; Koch I; Tomer R; Hofler H; Schuuring E; Kluin PM; Fend F; Quintanilla-Martinez L
    Blood; 2004 Aug; 104(4):1120-6. PubMed ID: 15090460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The significance of Melan-A-positive pagetoid melanocytosis in dysplastic nevi.
    Huwait H; Hijazi N; Martinka M; Crawford RI
    Am J Dermatopathol; 2014 Apr; 36(4):340-3. PubMed ID: 24736669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melanomas and Dysplastic Nevi Differ in Epidermal CD1c+ Dendritic Cell Count.
    Dyduch G; Tyrak KE; Glajcar A; Szpor J; Ulatowska-Białas M; Okoń K
    Biomed Res Int; 2017; 2017():6803756. PubMed ID: 28331853
    [No Abstract]   [Full Text] [Related]  

  • 35. Overexpression of p53 is a late event in the development of malignant melanoma.
    Lassam NJ; From L; Kahn HJ
    Cancer Res; 1993 May; 53(10 Suppl):2235-8. PubMed ID: 8485708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysplastic nevi.
    Clarke LE
    Clin Lab Med; 2011 Jun; 31(2):255-65. PubMed ID: 21549239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
    You Y; Wang SH; Zhang JF; Zheng SY
    Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression profile and molecular genetic regulation of cyclin D1 expression in epithelioid sarcoma.
    Lin L; Hicks D; Xu B; Sigel JE; Bergfeld WF; Montgomery E; Fisher C; Hartke M; Tubbs R; Goldblum JR
    Mod Pathol; 2005 May; 18(5):705-9. PubMed ID: 15578074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Typical, dysplastic, congenital, and Spitz nevi: a comparative immunohistochemical study.
    Palazzo J; Duray PH
    Hum Pathol; 1989 Apr; 20(4):341-6. PubMed ID: 2703228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo confocal microscopy for detection and grading of dysplastic nevi: a pilot study.
    Pellacani G; Farnetani F; Gonzalez S; Longo C; Cesinaro AM; Casari A; Beretti F; Seidenari S; Gill M
    J Am Acad Dermatol; 2012 Mar; 66(3):e109-21. PubMed ID: 21742408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.